{"id":48712,"date":"2025-11-20T16:30:57","date_gmt":"2025-11-20T08:30:57","guid":{"rendered":"https:\/\/flcube.com\/?p=48712"},"modified":"2025-11-20T16:30:58","modified_gmt":"2025-11-20T08:30:58","slug":"nona-biosciences-licenses-hcab-platform-to-pfizer-for-antibody-discovery","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48712","title":{"rendered":"Nona Biosciences Licenses HCAb Platform to Pfizer for Antibody Discovery"},"content":{"rendered":"\n

Nona Biosciences<\/strong>, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142<\/a>), announced a non\u2011exclusive licensing agreement with Pfizer<\/strong> (NYSE: PFE<\/a>) granting the pharma giant global access to Nona\u2019s proprietary HCAb technology platform<\/strong> for preclinical antibody discovery across multiple disease indications.<\/p>\n\n\n\n

Agreement Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Nona Biosciences<\/td><\/tr>
Licensee<\/strong><\/td>Pfizer Inc. (NYSE:\u202fPFE)<\/td><\/tr>
Deal Type<\/strong><\/td>Non\u2011exclusive licensing agreement<\/td><\/tr>
Technology<\/strong><\/td>HCAb platform (fully human heavy chain antibodies)<\/td><\/tr>
Scope<\/strong><\/td>Global access for preclinical antibody discovery<\/td><\/tr>
Financial Terms<\/strong><\/td>Upfront payment + regulatory, clinical, and commercial milestones (undisclosed)<\/td><\/tr>
Collaboration<\/strong><\/td>Nona to provide antibody discovery, development, and engineering services<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Profile<\/h2>\n\n\n\n